ATA341277A - Verfahren zur herstellung von arzneipraeparaten zur topischen behandlung von entzuendlichen zu- staenden der haut - Google Patents

Verfahren zur herstellung von arzneipraeparaten zur topischen behandlung von entzuendlichen zu- staenden der haut

Info

Publication number
ATA341277A
ATA341277A AT341277A AT341277A ATA341277A AT A341277 A ATA341277 A AT A341277A AT 341277 A AT341277 A AT 341277A AT 341277 A AT341277 A AT 341277A AT A341277 A ATA341277 A AT A341277A
Authority
AT
Austria
Prior art keywords
inflammable
skin
states
medical preparations
producing medical
Prior art date
Application number
AT341277A
Other languages
English (en)
Other versions
AT362869B (de
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of ATA341277A publication Critical patent/ATA341277A/de
Application granted granted Critical
Publication of AT362869B publication Critical patent/AT362869B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT0341277A 1976-05-13 1977-05-12 Verfahren zur herstellung von arzneipraeparaten zur topischen behandlung von entzuendlichen zustaenden der haut AT362869B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68594276A 1976-05-13 1976-05-13
US05/788,453 US4185100A (en) 1976-05-13 1977-04-20 Topical anti-inflammatory drug therapy

Publications (2)

Publication Number Publication Date
ATA341277A true ATA341277A (de) 1980-11-15
AT362869B AT362869B (de) 1981-06-25

Family

ID=27103704

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0341277A AT362869B (de) 1976-05-13 1977-05-12 Verfahren zur herstellung von arzneipraeparaten zur topischen behandlung von entzuendlichen zustaenden der haut

Country Status (12)

Country Link
US (1) US4185100A (de)
JP (1) JPS52145525A (de)
AT (1) AT362869B (de)
AU (1) AU512371B2 (de)
CA (1) CA1101334A (de)
DE (1) DE2721831A1 (de)
FR (1) FR2394293A1 (de)
GB (1) GB1544351A (de)
LU (1) LU77312A1 (de)
NL (1) NL190049C (de)
NZ (1) NZ184064A (de)
PH (1) PH14140A (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5794680A (en) * 1979-05-31 1980-12-04 E.R. Squibb & Sons, Inc. Corticosteroid stick formulations
JPS5636411A (en) * 1979-08-31 1981-04-09 Sumitomo Chem Co Ltd Liquid agent for external use
JPS574919A (en) * 1980-06-09 1982-01-11 Sankyo Co Ltd Anti-inflammatory for external use
JPS57203011A (en) * 1981-06-05 1982-12-13 Taiyo Yakuhin Kogyo Kk Anti-inflammatory external agent
US5635497A (en) * 1982-06-23 1997-06-03 Yamanouchi Europe B.V. Topical application compositions
CH655656B (de) * 1982-10-07 1986-05-15
US4602040A (en) * 1983-04-18 1986-07-22 Warner-Lambert Company Meclofenamic acid topical pharmaceutical composition
CA1229554A (en) * 1983-04-18 1987-11-24 Warner-Lambert Company Meclofenamic acid topical pharmaceutical composition
US4472431A (en) * 1983-08-18 1984-09-18 Methodist Hospital Of Indiana, Inc. Method for treatment of shock
AU613370B2 (en) * 1987-03-25 1991-08-01 Rockefeller University, The Prevention and treatment of the deleterious effects of exposing skin to the sun, and compositions therefor
US4775529A (en) * 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
US4897260A (en) * 1987-05-22 1990-01-30 The Rockefeller University Compositions that affect suppression of cutaneous delayed hypersensitivity and products including same
US4843099A (en) * 1987-07-20 1989-06-27 Colgate-Palmolive Company Device and composition for treatment of the gums
US4869897A (en) * 1987-10-22 1989-09-26 The Procter & Gamble Company Photoprotection compositions comprising sorbohydroxamic acid
US4847069A (en) * 1987-10-22 1989-07-11 The Procter & Gamble Company Photoprotection compositions comprising sorbohydroxamic acid and an anti-inflammatory agent
US4946671A (en) * 1987-10-22 1990-08-07 The Procter & Gamble Company Photoprotection compositions comprising sorbohydroxamic acid and an anti-inflammatory agent
US4847071A (en) * 1987-10-22 1989-07-11 The Procter & Gamble Company Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent
US5039513A (en) * 1987-10-22 1991-08-13 The Procter & Gamble Company Photoprotection compositions and methods comprising sorbohydroxamic acid
US4954332A (en) * 1987-10-22 1990-09-04 The Procter & Gamble Company Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent
EP0313305A3 (de) 1987-10-22 1990-02-07 The Procter & Gamble Company Chelatbildner enthaltende Lichtschutzmittel
US4959205A (en) * 1989-03-23 1990-09-25 Collagen Corporation Composition and method for treatment of dermal inflammation
US5093133A (en) * 1990-01-24 1992-03-03 Mcneil-Ppc, Inc. Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
DE4119170C2 (de) * 1991-06-11 2002-04-25 Geb Herber Miltner Mittel gegen Neurodermitis
US5324746A (en) * 1993-02-12 1994-06-28 Mckee Rex N Method of treating damaged mucosal and epithelial tissues with misoprostol
US6703009B1 (en) 1993-03-30 2004-03-09 Tendskin International Inc. Topical compositions and methods for treating pseudofolliculitis barbae and ingrown hair
US6001340A (en) * 1993-03-30 1999-12-14 Steven E. Rosen Topical compositions and methods for treating Pseudofolliculitis barbae and ingrown hair
US5807568A (en) * 1994-12-27 1998-09-15 Mcneil-Ppc, Inc. Enhanced delivery of topical compositions containing flurbiprofen
US5702720A (en) * 1995-12-22 1997-12-30 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of flurbiprofen
US5994399A (en) * 1997-03-27 1999-11-30 Mckee; Rex N. Method of regenerating collagen-containing tissues with misoprostol
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US5976566A (en) * 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US6617488B1 (en) * 1997-10-14 2003-09-09 Indicator Technologies, Inc. Method and apparatus for indicating the conditions in an absorbent article
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
AUPP583198A0 (en) * 1998-09-11 1998-10-01 Soltec Research Pty Ltd Mousse composition
US6503488B1 (en) 1998-11-17 2003-01-07 Tend Skin International, Inc. Topical compositions including deodorant compositions
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
ES2173678T3 (es) 1999-01-27 2002-10-16 Idea Ag Vacunacion no invasiva a traves de la piel.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
AU2000250701B2 (en) 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
FR2823670B1 (fr) * 2001-04-23 2004-12-17 Oreal Procede pour diminuer partiellement ou totalement les symptomes associes a la liberation d'histamine dans l'organisme
US7238680B2 (en) * 2001-06-01 2007-07-03 Rosen Steven E Topical compositions for veterinary uses
SI1273292T1 (en) * 2001-07-02 2004-12-31 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
DK3494995T3 (da) * 2002-03-01 2020-03-23 Chiesi Farm Spa Superfin formoterolformulering
TR200201556A2 (tr) * 2002-06-12 2004-01-21 Orva İlaç Sanayi̇ Ve Ti̇caret A. Ş. Kortikosteroid ve nonsteroidal antienflamatuar içeren farmasötik bileşim
CN100464741C (zh) * 2002-12-12 2009-03-04 盖尔德马研究及发展公司 含有酚衍生物和类维生素a的含水醇脱色素凝胶
US7241746B2 (en) * 2003-08-06 2007-07-10 Regena Therapeutics, Lc Method and composition for treating periodontal disease
US20080045909A1 (en) * 2004-02-23 2008-02-21 Strategic Science & Technologies, Llc. Topical Delivery of a Nitric Oxide Donor to Improve and Skin Appearance
EP1595531A1 (de) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren
WO2005102282A1 (en) * 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
EP1811961A2 (de) * 2004-11-12 2007-08-01 Idea Ag Erweiterte oberflächen-aggregate bei der behandlung von hauterkrankungen
US20070053984A1 (en) * 2005-03-03 2007-03-08 Monique Spann-Wade Topical gels compositions
US20070027217A1 (en) * 2005-05-27 2007-02-01 Ehrlich H Paul Composition and Method for Preventing Secondary Burn Ischemia
CA2611147C (en) 2005-06-01 2013-04-09 Stiefel Research Australia Pty Ltd. Topical emulsion formulation
WO2007103687A2 (en) * 2006-03-01 2007-09-13 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
US20080317684A1 (en) * 2006-09-06 2008-12-25 Isw Group, Inc. Topical Compositions
GB0622920D0 (en) * 2006-11-17 2006-12-27 Providence Capital Mangement Topical treatment
US8168670B2 (en) * 2007-11-21 2012-05-01 Teikoku Pharma Usa, Inc. Pyrazolone derivative emulsion formulations
EP2373346B1 (de) * 2008-09-10 2019-06-12 BioChemics, Inc. Ibuprofen zur topischen verabreichung
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2010151240A1 (en) * 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing ibuprofen
EP2445493A1 (de) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topische zusammensetzung mit naproxen
GB0915319D0 (en) * 2009-09-03 2009-10-07 Sharma Anant Combination medicament
EP2513343A4 (de) * 2009-12-18 2013-11-13 Exodos Life Sciences Ltd Partnership Verfahren und zusammensetzungen zur behandlung von hautentzündungen
WO2011076401A1 (de) 2009-12-23 2011-06-30 Holger Schankin Acetylsalicylsäure-haltige, im wesentlichen wasserfreie pharmazeutische zusammensetzungen
WO2012092523A1 (en) 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications
CN103429247A (zh) 2010-12-29 2013-12-04 战略科学与技术有限责任公司 勃起功能障碍和其它适应症的治疗
CN103717213B (zh) 2011-05-03 2016-11-09 阿波尼亚实验有限公司 布洛芬的透皮组合物及其使用方法
WO2012158405A2 (en) * 2011-05-16 2012-11-22 Pearlman Dale L Compositions and methods for the treatment of skin diseases
US8580286B2 (en) 2012-03-16 2013-11-12 Dale L. Pearlman Compositions and methods for the treatment of skin diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3243344A (en) * 1966-03-29 Anti-inflammatory barbituric acid derivatives
FR124F (de) 1964-04-29
NL6406688A (de) * 1964-06-05 1965-12-06
US3374145A (en) * 1965-03-11 1968-03-19 Armour Pharma Preparations and method for treating inflammatory conditions
US3461208A (en) * 1966-11-01 1969-08-12 Merck & Co Inc Indomethacin compositions
GB1268523A (en) * 1969-10-29 1972-03-29 Ici Ltd Dihydrofuran derivatives, the preparation thereof, and compositions containing the same
US3752826A (en) * 1970-01-26 1973-08-14 Mcneilab Inc Aroyl substituted pyrroles
US3721680A (en) * 1970-06-15 1973-03-20 Mc Neil Labor Inc 5-aroyl-2-(beta-hydroxyethyl)-1-loweralkylpyrroles
GB1335269A (en) * 1971-04-20 1973-10-24 Ici Ltd Dihydrofuran derivatives
DE2302005A1 (de) 1973-01-16 1974-07-18 Lege Artis Pharma Gmbh & Co Kg Mittel zum entfernen von warzen
US4012508A (en) * 1975-02-03 1977-03-15 Burton Verna M Topical composition and method

Also Published As

Publication number Publication date
JPS52145525A (en) 1977-12-03
NL7705276A (nl) 1977-11-15
FR2394293B1 (de) 1980-06-20
NZ184064A (en) 1979-03-16
CA1101334A (en) 1981-05-19
NL190049C (nl) 1993-10-18
AU512371B2 (en) 1980-10-09
NL190049B (nl) 1993-05-17
AU2507377A (en) 1978-11-16
LU77312A1 (de) 1977-08-24
GB1544351A (en) 1979-04-19
PH14140A (en) 1981-03-05
DE2721831A1 (de) 1977-11-24
AT362869B (de) 1981-06-25
FR2394293A1 (fr) 1979-01-12
US4185100A (en) 1980-01-22

Similar Documents

Publication Publication Date Title
ATA341277A (de) Verfahren zur herstellung von arzneipraeparaten zur topischen behandlung von entzuendlichen zu- staenden der haut
DD137355A5 (de) Verfahren zur herstellung von phthalazin-derivaten
DD128170A5 (de) Verfahren zur herstellung von praeparaten mit geregelter wirkstoffabgabe
ATA859578A (de) Verfahren zur herstellung von lokalanoesthetisch wirksamen kombinationspraeparaten
DD133680A5 (de) Verfahren zur herstellung von polyaetherpolyolen
DD132015A5 (de) Verfahren zur herstellung von trans-hexahydro-pyrido-indolen
DD128672A5 (de) Verfahren zur herstellung von m-aryloxybenzaldehyden
AT348995B (de) Verfahren zur herstellung von acylcyaniden
DD129777A5 (de) Verfahren zur herstellung von phenoxypropionsaeurederivaten
AT353968B (de) Verfahren zur herstellung von (14-14c)- daunorubicin und(14-14c)-doxorubicin
AT347926B (de) Verfahren zur herstellung von acylcyaniden
DD129903A5 (de) Verfahren zur herstellung von benzoylcyanid
DD131018A5 (de) Verfahren zur herstellung von 2-chlorsulfinylazetidin-4-onen
DD134871A5 (de) Verfahren zur herstellung von pyrrolochinoxalinonen und pyrrolobenzdiazepinonen
DD132013A5 (de) Verfahren zur herstellung von benzoylcyanid
DD133795A5 (de) Verfahren zur herstellung von 4a-aryloctahydro-1h-2-pyrindinen
AT348509B (de) Verfahren zur herstellung von acylcyaniden
DD130241A5 (de) Verfahren zur herstellung von benzoylcyanid
DD129782A5 (de) Verfahren zur herstellung von cholecystokinin-pancreozymin-octapeptidamid-sulfatester
DD129915A5 (de) Verfahren zur herstellung von 7-alkoxy-3-chlormethyl-3-cephemen
DD128591A5 (de) Verfahren zur herstellung von 2-oxo-1-pyrrolidinen
DD128953A1 (de) Verfahren zur herstellung von alkalizellulose
AT346477B (de) Verfahren zur herstellung von praeparaten zur lokalen behandlung der akne-vulgaris
DD130785A1 (de) Verfahren zur herstellung von 4-chlor-5-alkoxycarbonyl-2-methoxypyrimidinen
DD129792A5 (de) Verfahren zur herstellung von 1-oxadethiacephalosporinen

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee
ELA Expired due to lapse of time